HemoGenyx Pharmaceuticals PLC (LSE: HEMO) is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.
Location: United States, New York
Phone: +1 347-735-8380
Investors 2
| Date | Name | Website |
| - | 43North | 43north.or... |
| - | FirstXFoun... | firstxfoun... |
Mentions in press and media 18
| Date | Title | Description |
| 26.01.2023 | Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £4,056,250 | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR T... |
| 23.01.2023 | Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T 3rd Process Qualification Run Completed | LONDON, UK / ACCESSWIRE / January 23, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its th... |
| 09.01.2023 | Hemogenyx Pharmaceuticals PLC Announces Single CBR Can Treat Multiple Viruses | LONDON, UK / ACCESSWIRE / January 9, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor ("CBR") platform technology, designed to ... |
| 04.01.2023 | Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed | LONDON, UK / ACCESSWIRE / January 4, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its sec... |
| 12.12.2022 | Hemogenyx Pharmaceuticals PLC - HEMO-CAR-T First PQ Run Completed | HEMO-CAR-T First Process Qualification Run Completed LONDON, UK / ACCESSWIRE / December 12, 2022 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") HEMO, the biopharmaceutical group developing... |
| 22.08.2022 | Hemogenyx Pharmaceuticals PLC Announces Appointment of Director of Quality | Quality System Expert Joins Hemogenyx Pharmaceuticals as Director of Quality LONDON, UK / ACCESSWIRE / August 22, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood... |
| 15.08.2022 | Hemogenyx Pharmaceuticals PLC Announces Approval and Issuance of Antibody Patent | Approval and Issuance of Chinese Bi-specific Antibody Patent LONDON, UK / ACCESSWIRE / August 15, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pl... |
| 08.07.2022 | Hemogenyx Pharmaceuticals PLC Announces Investor Webinar Recording | LONDON, ENGLAND / ACCESSWIRE / July 8, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that following the live investor webinar presented by Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Ph... |
| 01.07.2022 | Hemogenyx Pharmaceuticals PLC Announces Change of Registered Office | LONDON, ENGLAND / ACCESSWIRE / July 1, 2022 / Hemogenyx Pharmaceuticals plc announces that its registered office address has changed with immediate effect to 6th Floor,60 Gracechurch Street, London, EC3V 0HR,United Kingdom. Enquiries: Hemog... |
| 30.06.2022 | Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting | LONDON, ENGLAND / ACCESSWIRE / June 30, 2022 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers o... |
Show more